Financials data is unavailable for this security.
View more
Year on year IRLAB Therapeutics AB 's revenues fell -90.71% from 61.14m to 5.68m. This along with an increase in the cost of goods sold expense has contributed to a reduction in net income from a loss of 113.41m to a larger loss of 177.84m.
| Gross margin | -138.17% |
|---|---|
| Net profit margin | -222.69% |
| Operating margin | -212.89% |
| Return on assets | -64.93% |
|---|---|
| Return on equity | -121.20% |
| Return on investment | -118.29% |
More ▼
Cash flow in SEKView more
In 2023, cash reserves at IRLAB Therapeutics AB fell by 141.47m. Cash Flow from Financing totalled 23.68m or 416.98% of revenues. In addition the company used 164.85m for operations while cash used for investing totalled 293.00k.
| Cash flow per share | -2.09 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 0.7332 |
|---|---|
| Tangible book value per share | -0.1703 |
More ▼
Balance sheet in SEKView more
| Current ratio | 0.8697 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 1.59 |
|---|---|
| Total debt/total capital | 0.6132 |
More ▼
